ArticleJournal of immunological methods2012
Isolation and characterization of pharmaceutical grade human pentraxins, serum amyloid P component and C-reactive protein, for clinical use.
Article in Journal of immunological methods, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 36 citations in OpenAlex.
- Neutrophils enhance the clearance of systemic amyloid deposits in a murine amyloidoma model.Frontiers in immunology · 2024Article
- C-reactive protein: structure, function, regulation, and role in clinical diseases.Frontiers in immunology · 2024Review
- Efficient expression and purification of rat CRP inFrontiers in immunology · 2024Article
- Serum amyloid P component accumulates and persists in neurones following traumatic brain injury.Open biology · 2023Article
- C-reactive protein predicts outcome in COVID-19: is it also a therapeutic target?European heart journal · 2021Article
- Dementia in the older population is associated with neocortex content of serum amyloid P component.Brain communications · 2021Article
- A Conformational Change in C-Reactive Protein Enhances Leukocyte Recruitment and Reactive Oxygen Species Generation in Ischemia/Reperfusion Injury.Frontiers in immunology · 2018Article
- The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.Frontiers in immunology · 2018Review
- Article
- Transitional changes in the CRP structure lead to the exposure of proinflammatory binding sites.Nature communications · 2017Article
- C-Reactive Protein Binds to Cholesterol Crystals and Co-Localizes with the Terminal Complement Complex in Human Atherosclerotic Plaques.Frontiers in immunology · 2017Article
- The pentraxins PTX3 and SAP in innate immunity, regulation of inflammation and tissue remodelling.Journal of hepatology · 2016Review
- Targeting C-Reactive Protein in Inflammatory Disease by Preventing Conformational Changes.Mediators of inflammation · 2015Review
- Protection of human podocytes from shiga toxin 2-induced phosphorylation of mitogen-activated protein kinases and apoptosis by human serum amyloid P component.Infection and immunity · 2014Article
- Efflux transport of serum amyloid P component at the blood-brain barrier.European journal of microbiology & immunology · 2013Article
- Pentraxins: structure, function, and role in inflammation.ISRN inflammation · 2013Review
- C-reactive protein and the biology of disease.Immunologic research · 2013Review
- Serum amyloid P inhibits granulocyte adhesion.Fibrogenesis & tissue repair · 2013Article
- Probing the phosphocholine-binding site of human C-reactive protein by site-directed mutagenesis.The Journal of biological chemistry · 1992Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 6 institutions in 2 countries.
Funding
Abstract
The human pentraxin proteins, serum amyloid P component (SAP) and C-reactive protein (CRP) are important in routine clinical diagnosis, SAP for systemic amyloidosis and CRP for monitoring the non-specific acute phase response. They are also targets for novel therapies currently in development but their roles in health and disease are controversial. Thus, both for clinical use and to rigorously elucidate their functions, structurally and functionally intact, pharmaceutical grade preparations of the natural, authentic proteins are required. We report here the production from normal human donor plasma and the characterization of the first such preparations. Importantly, we demonstrate that, contrary to reports using recombinant proteins and less well characterized preparations, neither CRP nor SAP stimulate the release by human peripheral blood mononuclear cells in vitro of any TNFα, IL-6 or IL-8, nor does SAP cause release of IL-1β or IL-10. Furthermore neither of our preparations was pro-inflammatory in mice in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.